Literature DB >> 22293301

Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts.

Shigehiro Shibata1, Yosuke Okamoto, Shigeatsu Endo, Kyoichi Ono.   

Abstract

The ultra-short acting, selective β(1)-adrenergic antagonists landiolol and esmolol are widely used perioperatively; however, little is known about their acute direct actions on the heart. The current study utilized the Langendorff perfused heart system to measure changes in cardiac function and hemodynamics in response to each drug. Furthermore, electrophysiological analysis was performed on isolated ventricular myocytes. Direct application of esmolol significantly decreased systolic left ventricular pressure and heart rate at concentrations > 10 µM, while it dose-dependently increased coronary perfusion pressure. Esmolol also shortened the action potential duration (APD) in a concentration-dependent manner, an action maintained even when the delayed rectifier K(+) current or ATP sensitive K(+) current was blocked. Moreover, esmolol inhibited both the inward rectifier K(+) current (I(K1)) and the L-type Ca(2+) current (I(CaL)) and increased the outward current dose-dependently. In contrast, landiolol had minimal cardiac effects. In the Kyoto Model computer simulation, inhibition of either I(K1) or I(CaL) alone failed to shorten the APD; however, an additional increase in the time-independent outward current caused shortening of the APD, equal to that induced by esmolol. In conclusion, esmolol directly inhibits cardiac performance significantly more so than landiolol, an effect revealed to be at least in part mediated by esmolol-induced APD shortening.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293301     DOI: 10.1254/jphs.11202fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

1.  Advantage of landiolol over esmolol? We doubt it!

Authors:  Guenther Frank; Robert Denham Fitzgerald
Journal:  Eur J Clin Pharmacol       Date:  2018-01-08       Impact factor: 2.953

2.  Answering letter to remark of Dr's Frank and Fitzgerald.

Authors:  Günther Krumpl
Journal:  Eur J Clin Pharmacol       Date:  2018-01-10       Impact factor: 2.953

3.  Acute rate control in atrial fibrillation: an urgent need for the clinician.

Authors:  Gheorghe-Andrei Dan; Anca R Dan; Andreea Ivanescu; Adrian C Buzea
Journal:  Eur Heart J Suppl       Date:  2022-06-13       Impact factor: 1.624

Review 4.  Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Juri Hodisch; Pavla Kadlecová; Bernhard Husch
Journal:  Cureus       Date:  2020-12-22

6.  Positive rate-dependent action potential prolongation by modulating potassium ion channels.

Authors:  Candido Cabo
Journal:  Physiol Rep       Date:  2022-06

7.  Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.

Authors:  Martin Unger; Andrea Morelli; Mervyn Singer; Peter Radermacher; Sebastian Rehberg; Helmut Trimmel; Michael Joannidis; Gottfried Heinz; Vladimír Cerny; Pavel Dostál; Christian Siebers; Fabio Guarracino; Francesca Pratesi; Gianni Biancofiore; Massimo Girardis; Pavla Kadlecova; Olivier Bouvet; Michael Zörer; Barbara Grohmann-Izay; Kurt Krejcy; Christoph Klade; Günther Krumpl
Journal:  Trials       Date:  2018-11-19       Impact factor: 2.279

Review 8.  Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.

Authors:  Yujiro Matsuishi; Bryan J Mathis; Nobutake Shimojo; Satoru Kawano; Yoshiaki Inoue
Journal:  Vasc Health Risk Manag       Date:  2020-04-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.